Title:
N-TERMINALLY TRUNCATED GALECTIN-3 AND ANTIBODIES FOR TREATING CANCER
Document Type and Number:
WIPO Patent Application WO2002100343
Kind Code:
A3
Abstract:
There is provided a composition having an effective amount of N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier or an effective amount of a nucleic acid sequence encoding N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier. Also provided by the present invention is a method of treating cancer by administering to a patient in need of such treatment an effective amount of N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier or an effective amount of a nucleic acid sequence encoding N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier. The present invention also provides an antibody that specifically binds to carbohydrate ligands of galectin-3. Further, there is provided an anti-cancer treatment having an effective amount of N-terminally truncated galectin-3 and a pharmaceutically acceptable carrier or an effective amount of nucleic acid sequence encoding N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier.
Inventors:
JARVIS GARY A (US)
JOHN CONSTANCE M (US)
LEFFLER HAKON (US)
JOHN CONSTANCE M (US)
LEFFLER HAKON (US)
Application Number:
PCT/US2002/018478
Publication Date:
March 17, 2005
Filing Date:
June 10, 2002
Export Citation:
Assignee:
MANDALMED INC (US)
JARVIS GARY A (US)
JOHN CONSTANCE M (US)
LEFFLER HAKON (US)
JARVIS GARY A (US)
JOHN CONSTANCE M (US)
LEFFLER HAKON (US)
International Classes:
A61K9/16; A61K38/17; A61K39/395; A61K47/48; C07K14/47; C07K16/28; (IPC1-7): A61K38/16; A61K39/395; A61K48/00; C07H21/04; C07K14/435; C07K16/32
Foreign References:
| US20020019009A1 | 2002-02-14 |
Other References:
PELLETIER ET AL.: "Specific recognition and cleavage of galectin-3 by Leishmania major through spieces-specific polygalactose epitope", J. BIOL. CHEM., vol. 277, 17 May 2002 (2002-05-17), pages 17663 - 17670, XP002984372
GONG ET AL.: "The NH2 Terminus of Galectin-3 Governs Cellular Compartimentalization and Functions in Cancer cells", CANCER RESEARCH, vol. 59, 15 December 1999 (1999-12-15), pages 6239 - 6245, XP002984373
DATABASE MEDLINE [online] CONSTANCE ET AL.: "Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer", XP002992511, accession no. dialog Database accession no. NLM12796408
See also references of EP 1534317A4
GONG ET AL.: "The NH2 Terminus of Galectin-3 Governs Cellular Compartimentalization and Functions in Cancer cells", CANCER RESEARCH, vol. 59, 15 December 1999 (1999-12-15), pages 6239 - 6245, XP002984373
DATABASE MEDLINE [online] CONSTANCE ET AL.: "Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer", XP002992511, accession no. dialog Database accession no. NLM12796408
See also references of EP 1534317A4
Download PDF: